Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep;119(6):724-736.
doi: 10.1038/s41416-018-0233-4. Epub 2018 Aug 21.

A Review of the Most Promising Biomarkers for Early Diagnosis and Prognosis Prediction of Tongue Squamous Cell Carcinoma

Affiliations
Free PMC article
Review

A Review of the Most Promising Biomarkers for Early Diagnosis and Prognosis Prediction of Tongue Squamous Cell Carcinoma

Aisha A Hussein et al. Br J Cancer. .
Free PMC article

Abstract

Background: There is a great interest in developing biomarkers to enhance early detection and clinical management of tongue squamous cell carcinoma (TSCC). However, the developmental path towards a clinically valid biomarker remains extremely challenging. Ideally, the initial key step in moving a newly discovered biomarker towards clinical implementation is independent replication. Therefore, the focus of this review is on biomarkers that consistently showed clinical relevance in two or more publications.

Methods: We searched PubMed database for relevant papers across different TSCC sample sources, i.e., body fluids (saliva, serum/plasma) and tissues. No restriction regarding the date of publication was applied except for immunohistochemistry (IHC); only studies published between 2010 and June 2017 were included.

Results: The search strategy identified 1429 abstracts, of which 96 papers, examining 150 biomarkers, were eventually included. Of these papers, 66% were exploratory studies evaluating single or a panel of biomarkers in one publication. Ultimately, based on studies that had undergone validation for their clinical relevance in at least two independent studies, we identified 10 promising candidates, consisting of different types of molecules (IL-6, IL-8, and Prolactin in liquid samples; HIF-1α, SOX2, E-cadherin, vimentin, MALAT1, TP53, and NOTCH1 in tissue biopsies) CONCLUSIONS: Although more exploratory research is needed with newer methods to identify biomarkers for TSCC, rigorous validation of biomarkers that have already shown unbiased assessment in at least two publications should be considered a high priority. Further research on these promising biomarkers or their combination in multi-institutional studies, could provide new possibilities to develop a specific panel for early diagnosis, prognosis, and individualized treatments.

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart illustrating studies selected
Fig. 2
Fig. 2
A diagram illustrating the promising biomarkers

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

References

    1. Vigneswaran N, Williams MD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral. Maxillofac. Surg. Clin. North. Am. 2014;26:123–141. - PMC - PubMed
    1. Mithani SK, Mydlarz WK, Grumbine FL, Smith IM, Califano JA. Molecular genetics of premalignant oral lesions. Oral. Dis. 2007;13:126–133. - PubMed
    1. Tota JE, et al. Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012. Oral. Oncol. 2017;67:146–152. - PubMed
    1. Moore SR, Johnson NW, Pierce AM, Wilson DF. The epidemiology of tongue cancer: a review of global incidence. Oral. Dis. 2000;6:75–84. - PubMed
    1. Hussein AA, et al. Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: a systematic review. Eur. J. Cancer. 2017;82:115–127. - PubMed

Substances

Feedback